Background: Nowadays, medical grade 316L stainless steel (316L SS) is being widely used for intravascular stents, and the drug-eluting stent (DES) system is able to significantly reduce the occurrences of in-stent restenosis. But the drugs and the polymer coating used in DES potentially induce the forming of late stent thrombosis. In order to reduce the occurrence of ISR after stent implantation, the development of novel drugs for DESs is urgently needed.
Methods: This study aimed to investigate the potential mechanisms of epigallocatechin-3-gallate (EGCG) on human umbilical vein endothelial cells (HUVEC) grown on 316L stainless steel (316L SS) using flow cytometry and Q-PCR methods.
Results: Our results showed that EGCG (12.5, 25, 50, 100 μmol/L) significantly inhibited HUVEC proliferation. Flow cytometry analysis indicated that EGCG (25, 50, 100 μmol/L) induced apoptosis. Moreover, qRT-PCRrevealed that genes associated with cell apoptosis (caspase-3, 8, 9, Fas) and autophagy (Atg 5, Atg 7, Atg 12) were up-regulated after EGCG treatment.
Conclusion: These findings indicate that EGCG possesses chemo preventive potential in stent coating which may serve as a novel new drug for stent implantation.



中文翻译：

---

EGCG 调节 316L 不锈钢支架植入人脐静脉内皮细胞的细胞凋亡

背景：如今，医用级316L不锈钢（316L SS）被广泛用于血管内支架，药物洗脱支架（DES）系统能够显着减少支架内再狭窄的发生。但 DES 中使用的药物和聚合物涂层可能会诱发晚期支架血栓的形成。为了减少支架植入后ISR的发生，迫切需要开发新的DESs药物。
方法：本研究旨在使用流式细胞术和 Q-PCR 方法研究表没食子儿茶素-3-没食子酸酯 (EGCG) 对在 316L 不锈钢 (316L SS) 上生长的人脐静脉内皮细胞 (HUVEC) 的潜在机制。
结果：我们的结果表明，EGCG（12.5、25、50、100 μmol/L）显着抑制 HUVEC 增殖。流式细胞仪分析表明EGCG（25、50、100 μmol/L）诱导细胞凋亡。此外，qRT-PCR 揭示与细胞凋亡（caspase-3、8、9、Fas）和自噬（Atg 5、Atg 7、Atg 12）相关的基因在 EGCG 处理后上调。
结论：这些发现表明EGCG在支架涂层中具有化学预防潜力，可作为一种新型支架植入新药。